eli lilly direct tirzepatide releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Eli Lilly slashes obesity drug

A 10-person case series from the State University of New York at Buffalo provided an overview of the effects of semaglutide use in people with newly diagnosed type 1 diabetes, with results suggesting use was associated with a complete elimination of the need for mealtime insulin doses among the entire study cohort, allowed 70% to eliminate basal insulin use within 6 months, and decreased the mean HbA1c from 11.7% at baseline to 5.9% at 6 months and 5.7% at 12 months

When combined with semaglutide, it can further support weight loss efforts

#glp1community #glp1 #glp1patches #real #bffr #unpopularopinion #creatorsearchinsights Yeah these did what they needed to do

Data were sampled at 10 kHz and analyzed with Clampfit (Molecular Devices) or MATLAB

Sermorelin can cause adverse reactions, though they are generally mild